We sent out a questionnaire to 112 women treated for diffuse toxic goitre 2-5 years earlier to evaluate the prevalence of problems with overweight after the disease. Of 87 responders, about 50% (irrespective of surgical or radioiodine treatment) reported weight problems, and we randomly selected 40 of these women (20 with and 20 without reported weight problems) for a clinical follow-up (32 appearing).
Introduction
Many individuals lose weight during the acute catabolic stage of hyperthyroidism. However, when summing up the final outcome of their disease, many patients tell their clinician that they have in fact gained in weight. Although in one study the mean final weight was only 2.5% above the premorbid weight,' a more recent study showed a final weight gain of 16% in a group of patients without dietary intervention and 9.8% in a group receiving dietary advice.2 These discrepant results are not readily explained, but one factor of importance may be a sex difference, the former study from a Veterans Administration Medical Center (USA) mainly comprising men and the latter, a study from Great Britain, comprising women. In our experience single patients have even opposed treatment for hyperthyroidism because of fear of weight gain after treatment, referring to anecdotal cases of pronounced gain of weight.
Since we felt that the clinical importance of this consequence of treated hyperthyroidism has been underestimated in clinical practice, we performed a retrospective study of patients who recently received radioiodine or surgical treatment for hyperthyroidism at our hospital. We only studied women, where the prevalence of thyroid disease is high, and where weight problems may be more pronounced judging from the British study.3
Patients and methods

Clinical background
In our region, individuals with hyperthyroidism are either selected for operative treatment (subtotal thyroid resection) or radioiodine treatment (100 Gy absorbed dose to the thyroid calculated after '3 I-uptake and scintigraphic and palpatory estimation of thyroid volume) according to generally accepted criteria. All patients planned for surgery are treated with anti-thyroid drugs (methimazole) until euthyroidism when levothyroxine is added for at least 3 weeks. Preoperative iodine treatment is given if the patient develops adverse reactions against anti-thyroid drugs. Individuals planned for radioiodine are treated with methimazole in case they have pronounced symptoms. Patients awaiting operative or radioiodine treatment are, when troubled by pronounced palpitations, also treated with betablockers. In only rare cases, with no obvious goitre, long-term methimazole administration is tried as a definitive treatment. After operation or radioiodine treatment, the patient is followed closely, especially during the first year. Treatment with levothyroxine is started when the individual shows laboratory and clinical evidence of hypothyroidism, individuals receiving levothyroxine thus only having experienced a brief period of slight hypothyroidism.
Study design
In 1989 we mailed a brief questionnaire to 112 randomly selected women then aged 23-54 years who had received treatment (surgery or radioiodine) for diffuse toxic goitre in [1984] [1985] [1986] [1987] . Patients with other diseases were excluded. The women were asked whether they had had problems with their weight after their thyroid disease, whether their problems now were slight or pronounced, and if they received treatment with levothyroxine.
From the responders of this inquiry we randomly selected 40 women, 10 with pronounced and 10 without weight problems in each treatment group (surgery or radioiodine). The women were invited to a follow-up with a detailed interview, blood sampling and a physical examination. In the interview the women were asked about weight problems during the course oftheir thyroid disease, and the estimated figures for body mass recorded (body mass before, minimum mass during, and mass one year after treatment). Information was also obtained regarding change of size of clothes, contacts with dieticians, 'Weight-Watchers' or similar organizations, present and past smoking habits, present medication and pregnancies since the thyroid disease. The present weight, height, heart rate, systolic and diastolic blood pressures as well as waist and hip circumference were recorded, and body mass index (BMI, present and estimated premorbid, kg/M2) and waist/hip ratio were calculated.
Biochemical methods
In the routine thyroid function evaluation done at the time of diagnosis, serum free thyroxine (analogue method) was assayed and an additional assay of serum thyrotrophin (TSH) or total 3,5,3'-triiodothyronine (T3) as described previously.3 The recalled patients were subjected to blood sampling after overnight fast 08.00-11.00 a.m. Serum TSH and free T4 were determined by immunochemiluminometric procedures: 'Magic Lite' TSH (reference interval 0.3-6.2 mU/l) and FT4 (reference interval 11-22 pmol/l), CIBA-Corning Diagnostics Corp., Medfield, MA, USA). The performance of these assays in our hands will be published separately. Serum total T4 (reference interval 70-160 nmol/l), total T3 (reference interval 1.5-2.7 nmol/l) and free T3 (reference interval 4.3-7.1 pmol/l) and 3,3',5'-triiodothyronine (reverse T3; reference interval 0.07-0.47 nmol/l) were analysed as decribed previously. 
Recall group
Of the 40 women selected from the responders of the questionnaire for a recall (20 with and 20 without weight problems; see Methods), 32 agreed to participate. The participation rate in the recall group with problems was similar to that of the group without weight problems (Table II) . The range of total weight change was -1 to + 26 kg for women with, and + 1 to + 15 kg for women without weight problems and, in all, 27 of the 32 women had gained in weight. We could not find any relation between the change in weight during Smoker after thyroid disease 8 6 Dietician, 'Weight Watchers', etc. after disease 5 1 Increased size of clothes after disease 13 the hyperthyroid phase and later weight increase.
No individuals experienced any period with pronounced hypothyroidism before levothyroxine substitution. There was a significant correlation between the final weight increase (weight at time of recall minus premorbid weight) for the whole group of women and estimated body mass index before thyroid disease (r = 0.54; P<0.005, see Figure 1 ). It might be argued that the weight increase might be associated with the therapeutic methods used here, surgery or radioiodine being much preferred to thyrostatic treatment. However, as indicated by the study reported by Alton and O'Malley,2 patients treated with thyrostatic drugs do also present with problems with weight.
We thus conclude that many and maybe even the majority of women experience a troublesome or alarming increase in weight after being treated for hyperthyroidism, and that this problem in some way is related to their thyroid disease. Our study shows that the problem does not seem to be related to method of treatment, severity of disease as judged by pretreatment thyroid hormone concentrations, change in smoking habits, treatment with levothyroxine or difference in peripheral conversion of thyroxine to triiodothyronine. We could, however, not obtain reliable information as regards the duration of the hyperthyroid phase. The fact that the weight gain of the 32 women correlated with the estimated premorbid BMI indicates that excess weight gainers may have had a premorbid weight problem exaggerated after the thyroid disease. However, many women with BMI within limits generally stated to be ideal (21-25 kg/m2) also showed dramatic increases in weight (Figure 1) .
It is therefore possible that after thyrotoxicosis there is a long-term disturbance in the neurochemical regulation of appetite and weight.'0 Another possibility is that the individual will have a diminished metabolic rate or rate of energy metabolism," due to a reduction during the thyrotoxic phase of lean body mass, which is not reversed after therapy. This is a possible mechanism in obese individuals with 'weight cycling"2 and for adolescent wrestlers with repeated weight loss and regain.'3 Many individuals in these groups are known to have pronounced problems in keeping their weight. All patients with hyperthyroidism should be given dietary advice. However, as indicated by the British study2 and also our study, in many cases such advice is of limited help, which might indicate that more profound lifestyle changes are needed.
